Trials / Active Not Recruiting
Active Not RecruitingNCT04619069
Intermittent Androgen Deprivation Therapy With or Without Stereotactic Body Radiotherapy for Molecularly Identified Hormone Sensitive Oligometastatic Prostate Cancer
Intermittent Androgen Deprivation Therapy With or Without Stereotactic Body Radiotherapy for Molecularly Identified Hormone Sensitive Oligometastatic Prostate Cancer: A Randomized Feasibility Study
- Status
- Active Not Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Sunnybrook Health Sciences Centre · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is evaluating whether adding stereotactic radiotherapy (a new, more focused type of radiotherapy) to treat all the tumours that are present will improve outcomes or not compared to drugs alone for patients who are negative on conventional imaging and positive on PSMA PET scan
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | SBRT | SBRT to all sites of metastatic disease as seen on PSMA PET scan |
| DRUG | Hormone therapy | Intermittent Hormone Therapy per physician discretion (Min. 8 months) |
Timeline
- Start date
- 2020-10-27
- Primary completion
- 2025-12-01
- Completion
- 2027-10-01
- First posted
- 2020-11-06
- Last updated
- 2025-04-17
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT04619069. Inclusion in this directory is not an endorsement.